— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected. — Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected. — Net product sales were $1.28 billion. — EYLEA net product sales in the US were $1.22 billion. — Sanofi and Bayer collaboration revenues were $748 million. — […]
— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected. — Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected. — Net product sales were $1.28 billion. — EYLEA net product sales in the US were $1.22 billion. — Sanofi and Bayer collaboration revenues were $748 million. — […]
— Regeneron Pharmaceuticals (NASDAQ: REGN)
reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected.
— Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected.
— Net product sales were $1.28 billion.
— EYLEA net product sales in the US were $1.22 billion.
— Sanofi and Bayer collaboration revenues were $748
million.
— R&D expenses totaled $683 million.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
